Home › Kanser sa Ovary › Oregon › Eugene
Pag-aaral pangklinika para sa Kanser sa Ovary sa Eugene, OR
9 pag-aaral para sa Kanser sa Ovary ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Eugene (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Nagre-recruitPhase 2
- Oncology Associates of Oregon, P.C. /ID# 275006, Eugene
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Nagre-recruitPhase 2
- Site 0316 - Willamette Valley Cancer Institute/Oncology Associates of Oregon, Eugene
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Nagre-recruitPhase 3
- USO - Oncology Associates of Oregon, P. C., Eugene
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Nagre-recruitPhase 2
- Willamette Valley Cancer Institute and Research Center /ID# 277714, Eugene
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Nagre-recruitPhase 3
- Oncology Associates of Oregon, P.C., Eugene
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Nagre-recruitPhase 3
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010), Eugene
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Nagre-recruitPhase 1/2
- USOR Oncology Associates of Oregon, P.C., Eugene
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Nagre-recruitPhase 2/3
- Oncology Associates of Oregon, P.C., Eugene
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Nagre-recruitPhase 2
- 517, Eugene
Pag-aaral para sa Kanser sa Ovary sa ibang lungsod
- Houston, TX89 pag-aaral
- New York City, NY69 pag-aaral
- Boston, MA61 pag-aaral
- Los Angeles, CA50 pag-aaral
- Nashville, TN49 pag-aaral
- Arlington, VA46 pag-aaral
- Philadelphia, PA44 pag-aaral
- Columbus, OH39 pag-aaral
- St. Louis, MO38 pag-aaral
- Chicago, IL36 pag-aaral
- San Antonio, TX31 pag-aaral
- Cleveland, OH30 pag-aaral
Iba pang pag-aaral sa Eugene
- Non-Small Cell Lung Cancer13 pag-aaral
- Kanser ng Endometrium8 pag-aaral
- Kanser sa Suso7 pag-aaral
- Chronic Lymphocytic Leukemia6 pag-aaral
- Multiple Myeloma6 pag-aaral
- Metastatic Cancer6 pag-aaral
- Kanser (lahat ng uri)6 pag-aaral
- Kanser sa Baga5 pag-aaral
- Degenerasyon ng Macula5 pag-aaral
- Paggamit ng Gamot at Adiksyon5 pag-aaral
- Obesity4 pag-aaral
- Overweight3 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.